Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered smartwatch could forecast Parkinson's worsening

NCT ID NCT07189468

Knowledge-focused Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will test whether artificial intelligence (AI) can predict how Parkinson's disease will progress and how patients will respond to medication. One hundred people with Parkinson's will wear a smartwatch and use a mobile app for one year. The AI models will analyze data from the watch, along with clinical and genetic information, to see if they can forecast motor decline and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a tool that helps doctors personalize Parkinson's treatment and predict how the disease will progress.
What could go wrong
This is an early study with only 100 people. The AI models may not work as well in real-world settings or for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Parkinson's disease patients

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Parkinson's disease diagnosis according to MDS criteria (Postuma et al., 2015) * Disease duration ranging from 5 to 10 years * Age 40-80 * Patients in stages 2 and 3 of the Hoehn and Yahr (a functional disability scale) in the ON condition * The participant is using a compatible smartphone * Written informed consent Exclusion Criteria: * Atypical Parkinsonian Syndrome * Second-line device-aided treatments * Patients with \>4 daily doses of L-DOPA * Daily levodopa equivalent dose \> 1500 mg * Ongoing hallucinations requiring short-term treatment adjustment * Inability to provide informed consent or participate in the study * Inability to use the smartwatch and/or the mAI-Care app - as judged by investigator * Lacking motivation to participate in study procedures - as judged by investigator * Under adult autonomy protection system, legal guardianship or incapacitation * Pregnant and breast-feeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease (disorder) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease (disorder)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Ruber Internacional

    Madrid, Spain

  • Queen Mary University of London

    London, United Kingdom

  • Technische Universität Dresden

    Dresden, Germany

  • University Hospital of Toulouse

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.